

Learner Notification

MED Learning Group

Screening Out Retinopathy: Pathways to Improving Diagnosis and Management in Patients with Diabetes

Various Dates: January 27 – May 30, 2023

Online

Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Implement evidence-based recommendations for diabetic retinopathy (DR) screening and monitoring
2. Examine the importance of early identification and timely treatment of DR and/or DME
3. Discuss treatments and dosing strategies for the individualized treatment of patients with DR and/or DME
4. Describe racial, ethnic and sex variations in the prevalence and disease course of DR
5. Cultivate a team-based approach in caring for the DR patient

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Judy E.	Kim	Alimera Sciences, Allergan, Apellis, Astellas, Bausch and Lomb, Clearside Biomedical, DORC, Genentech, Notal Vision, Novartis, Outlook Therapeutics, Regeneron: Consultant
Matthew	Frese	NA
Christina	Gallo	NA
Nicole	Longo	NA
Lauren	Welch	NA
Douglas	Cox	NA
Ana Maria	Albino	NA
Jessica	Feygin	NA
Daniel	DaSilva	NA
Jo	Shultz	NA

Questions? Email Certificate@AmedcoEmail.com